India’s First Cervical Cancer Vaccine: Get Details here!
Cervical Cancer Treatment: The Serum Institute of India (SII), the world’s largest vaccine manufacturer, has developed the country’s first cervical cancer vaccine, which will be available soon, according to the company and the government on Thursday.
According to the World Health Organization, cervical cancer is the fourth most common cancer among women worldwide, with an estimated 604,000 new cases and 342,000 deaths in 2020. That year, low- and middle-income countries accounted for roughly 90% of new cases and deaths worldwide.
Check out List Of Indian Nobel Laureates
Continue reading this article to learn more about the Cervical Cancer treatment, and India’s first vaccine against cervical cancer price in.
In India, how common is cervical cancer?
With 1.23 lakh cases and approximately 67,000 deaths per year, India accounts for roughly one-fifth of the global burden of cervical cancer.
Almost all cases of cervical cancer are linked to specific strains of human papillomavirus (HPV), a common virus spread through sexual contact. While the body’s immune system usually clears the HPV infection within two years, the virus can linger in a small percentage of people and turn some normal cells into abnormal cells, and then cancer, according to the Centers for Disease Control and Prevention (CDC).
What company created the new Cervical Cancer Vaccine?
Cervavac was developed in collaboration with the Government of India’s Department of Biotechnology(DBT) by the Pune-based Serum Institute of India. The project to develop the vaccine was implemented by the then secretary of the DBT, Dr. M K Bhan in 2011. Since then, DBT has conducted 30 meetings of scientific advisory groups and site visits to help review the scientific merit of the entire vaccine development process.
Cervavac was granted market authorization by the Drug Controller General of India on July 12, this year.
Cervical Cancer Vaccine India: Effectiveness and Prices
According to Dr. Rajesh Gokhale, HPV vaccines are given in two doses, and data has shown that antibodies developed after both doses can last up to six or seven years. Unlike Covid vaccines, the India’s first vaccine against cervical cancer may not require booster shots.
Until now, the only HPV vaccines available in India were made by foreign manufacturers and costed between Rs 2,000 and Rs 3,500 per dose. Cervavac is expected to be significantly less expensive, costing between Rs 200 and 400 (Vaccine Pricein India). It has also demonstrated a robust antibody response against all targeted HPV types, in all dose and age groups, that is nearly 1,000 times higher than the baseline.
The vaccine will be given in two doses to children aged 9 to 14, and three doses to those aged 15 to 26.
Hope you found this article on Cervical Cancer Vaccine Treatment useful.
Check IIT Guwahati Recruitment 2022 here.
Cervical Cancer Vaccine India FAQs
It could cost between 200 and 400 rupees.
The vaccine will be given in two doses to children aged 9 to 14, and three doses to those aged 15 to 26.
Females as young as 9 years old, as well as those aged 13-26 years who have not previously received vaccination, can be vaccinated.
It is critical to give it to both girls and boys before they have sexual contact and become infected with HPV. Girls and women over the age of 15, as well as those who are immunocompromised, such as those living with HIV, require three doses. The vaccine is ineffective once infected with HPV.
According to studies, the vaccine protects against HPV infection for at least ten years, though experts anticipate that protection will last much longer.
